Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
Disease-mediated alterations to drug disposition constitute a significant source of adverse drug reactions. Cisplatin (CDDP) elicits nephrotoxicity due to exposure in proximal tubule cells during renal secretion. Alterations to renal drug transporter expression have been discovered during nonalcohol...
Saved in:
Main Authors: | Joseph L. Jilek (Author), Kayla L. Frost (Author), Kevyn A. Jacobus (Author), Wenxi He (Author), Erica L. Toth (Author), Michael Goedken (Author), Nathan J. Cherrington (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients
by: Solène Marie, et al.
Published: (2023) -
Oligonucleotide therapies for nonalcoholic steatohepatitis
by: Sixu Li, et al.
Published: (2024) -
Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023) -
Serum Adipokine and Ghrelin Levels in Nonalcoholic Steatohepatitis
by: Mehmet Yalniz, et al.
Published: (2006) -
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
by: Milic S, et al.
Published: (2015)